0.4989 -0.031 (-5.87%) | 03-28 12:30 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 0.65 | 1-year : | 0.85 |
Resists | First : | 0.55 | Second : | 0.73 |
Pivot price | 0.51 | |||
Supports | First : | 0.28 | Second : | 0.23 |
MAs | MA(5) : | 0.52 | MA(20) : | 0.53 |
MA(100) : | 0.42 | MA(250) : | 0.43 | |
MACD | MACD : | 0 | Signal : | 0 |
%K %D | K(14,3) : | 35.2 | D(3) : | 37.4 |
RSI | RSI(14): 50.6 | |||
52-week | High : | 1.2 | Low : | 0.22 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ NRXP ] has closed above bottom band by 47.2%. Bollinger Bands are 38.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
If tomorrow: | Open lower | Open higher |
High: | 0.55 - 0.55 | 0.55 - 0.56 |
Low: | 0.5 - 0.51 | 0.51 - 0.51 |
Close: | 0.53 - 0.53 | 0.53 - 0.53 |
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.
Thu, 28 Mar 2024
NRx Pharmaceuticals announces reverse stock split By Investing.com - Investing.com Australia
Thu, 28 Mar 2024
NRx Pharmaceuticals announces reverse stock split to maintain Nasdaq listing (NASDAQ:NRXP) - Seeking Alpha
Thu, 28 Mar 2024
NRx Pharmaceuticals reports progress and outlook - Investing.com India
Thu, 28 Mar 2024
NRx Pharmaceuticals (NASDAQ:NRXP) Reports Preliminary Fourth Quarter and Full Year 2023 Financial Results and ... - PR Newswire
Thu, 28 Mar 2024
NRx Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing - Yahoo Finance
Tue, 26 Mar 2024
UPDATE: NRx Pharmaceuticals (NASDAQ: NRXP) to Report Fourth Quarter and Full Year 2023 Financial Results on ... - Yahoo Finance
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 92 (M) |
Shares Float | 58 (M) |
Held by Insiders | 31.1 (%) |
Held by Institutions | 4.4 (%) |
Shares Short | 2,710 (K) |
Shares Short P.Month | 2,870 (K) |
EPS | -0.5 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | -0.08 |
Profit Margin | 0 % |
Operating Margin | 0 % |
Return on Assets (ttm) | -109 % |
Return on Equity (ttm) | -682.7 % |
Qtrly Rev. Growth | 0 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 0 |
EBITDA (p.s.) | -0.36 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | -27 (M) |
Levered Free Cash Flow | -15 (M) |
PE Ratio | -1.02 |
PEG Ratio | 0 |
Price to Book value | -6.33 |
Price to Sales | 0 |
Price to Cash Flow | -1.75 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |